Is 'Sticky Gunk' In Your Brain The Reason Behind Alzheimer's Disease?

Updated Mar 20, 2025 | 08:53 AM IST

SummaryThe new findings is based on a subset of 22 participants who received amyloid-removing drugs the longest, on average eight years.
Alzheimer's Disease

Credits: Canva

An experimental treatment happens to be the solution to delay Alzheimer's symptoms in some people. These people are the ones who are genetically destined to get the disease in their 40s or 50s. These new findings form ongoing research has now been caught up in Trump administration funding delas. The early results of the study has been published on Wednesday and the participants too are worried that politics could cut their access to a possible lifeline.

One of the participants had said, "It is still a study but it has given me an extension to my life that I never banked on having." The participant is named Jake Henrichs, form New York City, who is 50 years old. He is one of them to be treated in that study for more than a decade now and has remained symptom-free despite inheriting an Alzheimer's-causing gene that had killed his father and brother around the same age.

Slowing Down The Symptoms

Two drugs which can modestly slow down early-stage Alzheimer's are sold in the United States. These drugs clear the brain of one of its hallmarks, a sticky gunk-like part called the amyloid. However, there have not been any hints that removing amyloid far earlier, way many years before the first symptoms appear, may postpone the disease.

How Was The Research Conducted?

The research is led by Washington University in St Louis, which involved families that passed down rare gene mutation as participants. This meant it was almost guaranteed that they will develop symptoms at the same age their affected relatives did.

The new findings is based on a subset of 22 participants who received amyloid-removing drugs the longest, on average eight years. Long-term amyloid removal cut in half their risk of symptom onset. The study is published in the journal Lancet Neurology.

Washington University's Dr Randall Bateman, who directs the Dominantly Inherited Alzheimer's Network of studies involving families with these rare genes says, "What we want to determine over the next five years is how strong is the protection. Will they ever get the symptoms of Alzheimer’s disease if we keep treating them?”

The researchers before though did not know what exactly caused Alzheimer's which affects nearly 7 million Americans, most of them in their later life. However, it is clear that these silent changes occur in the brain at least two decades before the first symptom shows up. The big contributor. At some point amyloid buildup can trigger a protein named tau that then starts to kill neurons, which can lead to cognitive decline.

Researchers are now thus studying the Tau-fighting drugs and are looking into other factors, like inflammation, brain's immune cells and certain virus.

The National Institute of Health (NIH) has expanded its focus as researchers have found more reasons for Alzheimer's. In 2013, the NIH's National Institute on Aging funded 14 trials of possible Alzheimer's drugs over a third targeting amyloid. By last fall, there were 68 drugs and 18% of them target amyloid. However, there are scientists too who think that amyloid is not everything and their is way more in the brain tissue, immune cells, and more which can be studied.

End of Article

US Loses Measles Elimination Status After 26 Years: What Does It Mean?

Updated Nov 16, 2026 | 06:35 AM IST

SummaryThe United States has lost its measles elimination status that it had obtained in 2000 after decades of public health efforts.
US Loses Measles Elimination Status After 26 Years: What Does It Mean?

Credit: AI-generated image

The United States has lost its measles elimination status after more than a year of sustained transmission, marking a major setback for a public health achievement the country obtained in 2000.

The decision by the Pan American Health Organization (PAHO) comes after a sharp rise in infections as the US reported more than 5,400 measles cases in 2026. PAHO is expected to formally announce the decision on November 17.

According to the US Centers for Disease Control and Prevention (CDC), the country had recorded 5,412 cases as of November 15, resulting in more than 590 hospitalisations and at least six deaths. Some states have reported additional fatalities. Cases have been confirmed in 45 states and Washington, DC.

The United States had maintained its measles elimination status for more than 25 years. However, outbreaks that began in 2025 continued spreading into 2026. Approximately one-third of this year's cases were linked to those ongoing outbreaks.

What Does Losing Measles Elimination Status Mean?

Also read: US Set To Lose Measles-Elimination Status After 26 Years: Prof Devi Sridhar Explains Reasons Behind Resurgence

Measles elimination does not mean a country has no cases of the disease. It means that local transmission has been interrupted and that occasional outbreaks do not lead to sustained community spread.

Under the World Health Organization's definition, a country loses elimination status when it cannot stop continuous local transmission for at least 12 months.

The United States first achieved measles elimination status in 2000, after decades of vaccination efforts dramatically reduced infections. Imported cases and smaller outbreaks still occurred, but public-health measures and vaccination coverage helped contain them.

The current situation is different because the virus has continued circulating through communities for more than a year, creating ongoing chains of transmission.

CBS News medical correspondent Dr Céline Gounder explained the implications, "It means that we're at risk of being exposed to measles and getting measles if we're not vaccinated," Gounder said. "It means ERs and pediatricians need to consider measles in anyone with a fever and rash, whether they've traveled overseas or not. And we may now become an exporter of measles to other countries."

Measles Cases Are Rising In The US

Also read: US Measles Cases Cross 5,000 For First Time Since 1991; Country Risks Losing Elimination Status

Declining childhood vaccination coverage has left more communities vulnerable to outbreaks. Measles is among the most contagious infectious diseases, and the virus can spread rapidly when it enters populations with gaps in immunity.

According to CDC data, 96% of people infected in 2026 were either unvaccinated or had an unknown vaccination status. Only 2% of reported cases were among people who were fully vaccinated.

The country recorded 2,242 cases in 2025, its highest annual total in more than three decades at the time. The number has more than doubled in 2026.

Pennsylvania has reported the largest outbreak, with more than 1,500 cases and seven deaths this year. Wisconsin has reported two child deaths, while New York recorded its first measles death in more than 30 years.

How Can US Regain Measles Elimination Status?

People who have not received the measles vaccine are at the greatest risk of infection. However, infants who are too young to be vaccinated, pregnant women and people with weakened immune systems are the most vulnerable.

Measles can cause complications like pneumonia and encephalitis or inflammation of the brain. In some cases, it can lead to permanent neurological complications, hearing loss and death.

Children who have not received the recommended doses of the measles, mumps and rubella (MMR) vaccine are especially vulnerable.

The CDC recommends two doses of the MMR vaccine. According to the public health experts, two doses are approximately 97% effective against measles.

Losing elimination status does not mean the country cannot regain it. However, sustained efforts to interrupt transmission will be necessary.

PAHO recommends maintaining measles vaccination coverage of at least 95%, alongside strong disease surveillance, laboratory testing and rapid outbreak response. Dr Omer Awan, an epidemiologist and public health contributor for Forbes, explained the importance of vaccination.

"It's frustrating and heartbreaking ... because we have the tools to fight this. The tool is the MMR vaccine, which we know is 97% effective at preventing the onset of measles," Awan said.

End of Article

Lilly's Obesity Drugs: Foundayo Becomes First GLP-1 Pill Approved In China, Experimental Combo Shows Promise

Updated Nov 15, 2026 | 10:00 PM IST

SummaryEli Lilly weight loss pill Foundayo beat its Novo Nordisk's Wegovy by securing regulatory approval in China. Lilly also reported promising results from a clinical trial testing an experimental combination drug involving eloralintide and tirzepatide.
Lilly's Obesity Drugs: Foundayo Becomes First GLP-1 Pill Approved In China, Experimental Combo Shows Promise

Credit: AI-generated image

Eli Lilly is rapidly expanding its presence in the global obesity treatment market. Its oral weight-loss drug Foundayo has received approval in China, becoming the first GLP-1 pill to get approved in the country.

In another development, its experimental drug combination of eloralintide and tirzepatide recently reported substantial weight loss in an early-stage clinical trial.

The developments come as pharmaceutical companies compete to develop more convenient treatments for obesity, including oral alternatives to injections and dual and triple-acting medicines.

Foundayo Weight Loss Pill Gets Approval In China

Also read: World Diabetes Day: Why Some Diabetes Patients May Not Be Suitable For GLP-1 Treatment, Experts Explain

RecnChina approved orforglipron, marketed as Foundayo in the US, making it the first GLP-1 medication in pill form approved for weight management in the country. Until now, Chinese regulators had authorised GLP-1 medicines for obesity treatment only as injections.

The approval gives Lilly an early advantage over its rival Novo Nordisk, which has also applied to market its oral Wegovy treatment in China.

Foundayo contains orforglipron, an oral, small-molecule GLP-1 receptor agonist. GLP-1 medicines mimic the action of a naturally occurring gut hormone involved in appetite regulation and blood sugar control.

Unlike injectables like Wegovy and Zepbound, Foundayo is taken once daily as a tablet. It can also be taken without restrictions on food and water intake, which may make it a more convenient option for people who prefer not to use injections.

In separate clinical trials, Foundayo produced an average weight reduction of approximately 11% over 72 weeks, while oral Wegovy achieved around 14% over 64 weeks. These results come from different studies.

Experimental Combination EloraTZP Shows Up To 23.3% Weight Loss

Also read: Stopping Mounjaro & Zepbound May Trigger Hallucinations, Mania & Other Psychiatric Symptoms

In another development announced on November 14, Lilly reported promising Phase 2 results for EloraTZP, an experimental combination of eloralintide and tirzepatide.

The combination brings together two medicines that act on appetite and metabolism differently. Tirzepatide, the active ingredient in Zepbound, activates GIP and GLP-1 receptors. Eloralintide is an investigational drug that acts on amylin receptors, which are involved in regulating appetite and feelings of fullness.

In adults with obesity and type 2 diabetes, participants receiving EloraTZP achieved weight loss of up to an average of 23.3% after 48 weeks. Their average starting weight was 232.4 pounds (approximately 105.4 kg). Up to 60% of participants no longer met the BMI criteria for obesity at the end of the study.

The combination also reduced the average blood glucose levels over approximately three months, by up to 2.9 percentage points. Up to 77% of participants achieved normal blood sugar levels, according to Lilly.

However, these are Phase 2 findings reported by Lilly, and the full trial results have not yet been published. Larger studies will be needed to establish the combination's safety and effectiveness in obesity treatment.

More Updates From Lilly

Lilly's latest update included findings from its Phase 3 SURMOUNT-ADOLESCENTS trials, which evaluated Zepbound in adolescents aged 12 to under 18 with obesity.

Participants experienced an average BMI reduction of 21.4% after 72 weeks. More than half no longer met the BMI criteria for obesity. They also reported improvements in aspects of quality of life due to weight reduction, including physical comfort and better body image.

Separately, the company reported Phase 3 findings for retatrutide, an experimental once-weekly medicine that activates three hormone receptors: GIP, GLP-1 and glucagon.

In trials involving adults with obesity, it reduced the severity of obstructive sleep apnoea and knee osteoarthritis pain. Retatrutide, an investigational drug, is not approved for general medical use.

End of Article

91% Of Indian Studies Spanning 50 Years Link Air Pollution To Diabetes, Heart Disease And Cancer

Updated Nov 15, 2026 | 08:00 PM IST

SummaryA recent review of 184 epidemiological studies by Centre for Research on Energy and Clean Air (CREA) found that air pollution is linked to at least one adverse health outcome.
91% Of Indian Studies Spanning 50 Years Link Air Pollution To Diabetes, Heart Disease And Cancer

Credit: AI-generated image

Air pollution in India, especially during winter after Diwali, is one of the alarming environmental and health concerns currently. While we are aware about its adverse effects on lungs and respiratory health, a recent review of five decades of Indian research has suggested its damages may extend to other bodily functions too.

A review of five decades of Indian research has found that more than 91% of epidemiological studies examining the health effects of air pollution reported at least one adverse health effect. These health conditions ranged from cardiovascular and metabolic diseases to pregnancy complications and cancer.

The analysis, conducted by the Centre for Research on Energy and Clean Air (CREA), examined 184 peer reviewed epidemiological studies published between 1975 and 2025.

Out of these, 169 reported at least one positive link between air pollution and an adverse health effect. The findings cement evidence linking polluted air to a wider range of health problems.

What Did The Analysis Report?

Also read: World Diabetes Day 2026: Is India's Toxic Air Adding To Its Diabetes Crisis? What Experts Say

Respiratory diseases were the most frequently investigated health outcomes, featuring in 86 of the 184 studies. Sixteen studies examined mortality, while 11 focused on cardiovascular diseases.

Other research investigated connections between air pollution and diabetes, pregnancy complications, low birth weight, impaired child growth, cancers and other neoplasms, blood disorders, neurological and mental health conditions, metabolic disorders, sleep problems, eye diseases and chronic kidney and bone conditions.

The review also found that the evidence was not limited to privately funded or independent research. Of the 46 government-funded studies included, 44 reported increased health risks.

Similarly, 77 of the 81 studies affiliated with government institutions reported adverse health associations. These institutions included the Indian Council of Medical Research (ICMR), All India Institute of Medical Sciences (AIIMS), the Central Pollution Control Board (CPCB) and the Ministry of Health and Family Welfare.

The 91.8% figure represents the proportion of studies that reported at least one positive association with a health outcome.

Indian Air Pollution Crisis

Delhi accounted for the highest number of studies i.e. 26, followed by Punjab with 13, and Maharashtra and Uttar Pradesh with 11 each. However, the review also highlighted a wide gap in research outside urban centres.

Only 40 studies examined rural populations. Of these, 38 reported at least one adverse health effect linked with air pollution exposure.

The studies accounted for several sources of exposure, including outdoor pollution, household cooking and heating fuels, indoor environments like homes and workplaces, and occupational exposure.

Also read: Delhi Air Pollution: Are Online Classes And Indoor Time Adding To Children's Anxiety?

Polluted Air Can Affect Heart And Metabolism

Fine particulate matter, like PM2.5, can travel deep into the lungs and enter the bloodstream. It can cause inflammation and oxidative stress, processes that may affect blood vessels, metabolic regulation and other organs.

Indian research has also examined the relationship between PM2.5 exposure and type 2 diabetes. A study involving 12,064 adults in Delhi and Chennai, published in BMJ Open Diabetes Research & Care in 2023, found that higher long-term PM2.5 exposure was associated with increased fasting blood glucose, HbA1c and the risk of developing type 2 diabetes. The findings were observational and do not establish that pollution alone caused diabetes.

Air pollution has also been associated with cardiovascular conditions, including hypertension, ischaemic heart disease and stroke. Meanwhile, the CREA review included studies examining neoplasms, a category that includes cancers. However, the review does not establish that 91% of studies independently linked pollution to diabetes, heart disease and cancer. These were among several health outcomes investigated.

India Needs A Better Clean-Air Strategy

The review suggests that air pollution policies need to address the wider picture. Studies examined particulate matter, including PM2.5 and PM10, as well as nitrogen dioxide, sulphur dioxide, ozone, carbon monoxide, black carbon and heavy metals.

CREA has called for stronger air-quality standards, better pollution monitoring, stricter emission limits for industries and power plants, and measures to reduce indoor pollution from solid fuels. It has also emphasised the need to include rural populations in the next phase of India's National Clean Air Programme.

End of Article